glp-1 agonists for type 2 diabetes Clinical Focus on in Mellitus Effect of combination treatment with

These microbiome alterations are associated with greater intestinal barrier integrity, decreased endotoxemia, and increased synthesis of short-chain fatty acids

Individuals who experience nausea from GLP-1 medications tend to be more common when first starting treatment or increasing the dosage

Understanding GLP-1 Agonists GLP-1 agonists, or glucagon-like peptide-1 receptor agonists, are a class of medications primarily used to treat type 2 diabetes and aid in weight management

Reich N, Holscher C (2022) The neuroprotective effects of glucagon-like peptide 1 in Alzheimers and Parkinsons disease: an in-depth review

Opportunities Expanding Use in Obesity Management The growing use of GLP-1 analogues for the treatment of obesity is one of the largest opportunities

The choice depends on your BMI, comorbidities, and readiness for permanent change